Technical Analysis for ARAV - Aravive, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
New 52 Week Closing Low | Bearish | 0.00% | |
180 Bearish Setup | Bearish Swing Setup | 0.00% | |
Calm After Storm | Range Contraction | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Calm After Storm | Range Contraction | -13.39% | |
Narrow Range Bar | Range Contraction | -13.39% | |
Inside Day | Range Contraction | -13.39% | |
Wide Bands | Range Expansion | -13.39% | |
Oversold Stochastic | Weakness | -13.39% |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 03/13/2024
Aravive, Inc., a clinical stage biotechnology company, focuses on developing therapies for solid tumors and hematologic malignancies. It is developing AVB-S6-500, a GAS6 binding protein and AXL decoy receptor, for the treatment of ovarian cancer, as well as for renal cell carcinoma, acute myeloid leukemia, triple negative breast cancer and pancreatic cancer. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. is based in Houston, Texas.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Solid Tumors Breast Cancer Cell Biology Acute Myeloid Leukemia Ovarian Cancer Treatment Of Breast Cancer Pancreatic Cancer Carcinoma Hematologic Malignancies Bemcentinib Renal Cell Carcinoma Treatment Of Ovarian Cancer Triple Negative Breast Cancer
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Solid Tumors Breast Cancer Cell Biology Acute Myeloid Leukemia Ovarian Cancer Treatment Of Breast Cancer Pancreatic Cancer Carcinoma Hematologic Malignancies Bemcentinib Renal Cell Carcinoma Treatment Of Ovarian Cancer Triple Negative Breast Cancer
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 2.46 |
52 Week Low | 0.0401 |
Average Volume | 2,379,744 |
200-Day Moving Average | 0.70 |
50-Day Moving Average | 0.12 |
20-Day Moving Average | 0.09 |
10-Day Moving Average | 0.07 |
Average True Range | 0.01 |
RSI (14) | 21.88 |
ADX | 30.78 |
+DI | 11.35 |
-DI | 39.70 |
Chandelier Exit (Long, 3 ATRs) | 0.10 |
Chandelier Exit (Short, 3 ATRs) | 0.07 |
Upper Bollinger Bands | 0.16 |
Lower Bollinger Band | 0.03 |
Percent B (%b) | 0.11 |
BandWidth | 146.03 |
MACD Line | -0.02 |
MACD Signal Line | -0.02 |
MACD Histogram | -0.0065 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.05 | ||||
Resistance 3 (R3) | 0.05 | 0.05 | 0.05 | ||
Resistance 2 (R2) | 0.05 | 0.05 | 0.05 | 0.05 | |
Resistance 1 (R1) | 0.04 | 0.04 | 0.04 | 0.04 | 0.05 |
Pivot Point | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 |
Support 1 (S1) | 0.04 | 0.04 | 0.04 | 0.04 | 0.03 |
Support 2 (S2) | 0.04 | 0.04 | 0.04 | 0.03 | |
Support 3 (S3) | 0.03 | 0.04 | 0.03 | ||
Support 4 (S4) | 0.03 |